BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24609941)

  • 1. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study.
    Yu WW; Zhu ZF; Fu XL; Zhao KL; Mao JF; Wu KL; Yang HJ; Fan M; Zhao S; Welsh J
    Strahlenther Onkol; 2014 Oct; 190(11):979-86. PubMed ID: 24609941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
    Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
    J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
    BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
    Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
    Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.
    Fakhrian K; Oechsner M; Kampfer S; Schuster T; Molls M; Geinitz H
    Strahlenther Onkol; 2013 Apr; 189(4):293-300. PubMed ID: 23443611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.
    Butler EB; Teh BS; Grant WH; Uhl BM; Kuppersmith RB; Chiu JK; Donovan DT; Woo SY
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):21-32. PubMed ID: 10477002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
    Ristau J; Thiel M; Katayama S; Schlampp I; Lang K; Häfner MF; Herfarth K; Debus J; Koerber SA
    Radiat Oncol; 2021 Feb; 16(1):23. PubMed ID: 33522923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
    Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I
    Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
    Sakanaka K; Ishida Y; Fujii K; Ishihara Y; Nakamura M; Hiraoka M; Mizowaki T
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):191-201. PubMed ID: 32768158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT.
    Schild MH; Schild SE; Wong WW; Vora SA; Keole SR; Vargas CE; Daniels TB; Ezzell GA; Nguyen BD; Roarke MC
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1021-1025. PubMed ID: 28332984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ; Wang L; Han C; Liu LL
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
    [No Abstract]   [Full Text] [Related]  

  • 14. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
    Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
    Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome.
    Ishida Y; Sakanaka K; Fujii K; Itasaka S; Mizowaki T
    J Radiat Res; 2019 Jul; 60(4):517-526. PubMed ID: 31083715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
    Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
    Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced toxicity with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy compared with conventional two-dimensional radiotherapy for esophageal squamous cell carcinoma: a secondary analysis of data from four prospective clinical trials.
    Deng JY; Wang C; Shi XH; Jiang GL; Wang Y; Liu Y; Zhao KL
    Dis Esophagus; 2016 Nov; 29(8):1121-1127. PubMed ID: 26663710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.